Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
← catalyst calendarSponsored by Genfit (industry) · GNFT.PA — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
15actual
Sites
26
Countries
Belgium, France, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-02 | actual | When the study began enrolling |
| Primary completion | 2025-10-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-15 | actual | The whole study's end, after follow-up |
| First posted | 2023-06-12 | actual | When this record first appeared on the registry |
| Results posted | 2026-07-23 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute-On-Chronic Liver Failure
- Ascites
Interventions
- Drug: VS-01 on top of SOC
- Other: SOC (Control Group)
Primary outcome
what the primary-completion date above is the date OFChronic Liver Failure Consortium (CLIF-C) ACLF Score at Day 7
measured Day 7
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-01-27 · 2.9 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-08-27 · 1.6 MB · SAP_001.pdf
Permalink · GNFT.PA's whole pipeline · Catalyst calendar · Every registered study · What changed